Euronext Amundi GR (SAMUG)

CIIT..............................https://stockcharts.com/sc3/ui/?s=CIIT&p=w&b=5&g=0&id=p86431144783

Quantum Cyber a defense consolidation/platform play:

* autonomous drone systems,
* counter-drone capabilities,
* encrypted communications,
* multi-domain unmanned systems,
* manufacturing capacity tied to government opportunities.

VSME...................https://stockcharts.com/sc3/ui/?s=VSME&p=w&b=5&g=0&id=p86431144783

August some will be eligible. Remember the Amazon employees cashing in for pennies on the dollar?. $150 was my entry point around 2PM it filled.

This is going to be interesting with Russell coming up, but I'd bet institution arbitragers already have what they need.

I'l

proprietary technology? BIEL does not even have a patent you dunce.

1. Revenue Growth
This is the most important metric.
Questions to ask:

If revenue grows meaningfully quarter-over-quarter, it would support management’s growth narrative.
2. Cash Flow and Operating Results
Revenue alone isn’t enough.
Look for:

SDOT..........................https://stockcharts.com/sc3/ui/?s=SDOT&p=w&b=5&g=0&id=p86431144783

Connecticut is becoming a credible technology and manufacturing area for drones, especially where drones overlap with aerospace, defense, composites, precision machining, and U.S.-based production. It’s not the dominant U.S. drone hub, but it has some characteristics that make it attractive.

Another COBBED close at .0018 yesterday! This stock is absolutely pathetic no matter what folks say here!!! This shot continues to decline daily but …”soon”
$TWOH💩💩💩💩💩= .0018!!!!👎👎👎
Swirling the toilet bowl daily….

Some market order sell… some idiot probably didn’t realize 

Analysis of the June 10 update, getting real....we will be drilling within days. War news was good going into the weekend. Guess I need to update my crude price in the tracker to $60. Anyway from here the drill bit does the talking.

https://christians4zionoil.freeforums.net/thread/6

Ask Amazon? More like ask why they don't sell Lunar on Amazon. Did something happen when they tried selling Acute/Defense with them?

LMAO ok Beer, I know where you get your info. Send my regards. PBM decisions are not what you think. 
This is cute. 
“Amarin's benefit from the science will come from Europe and ROW, and Guideline upgrades in those regions.”

The OUS Revenue Reality Check
Looking a

BofA’s Hartnett Warns Bullish Positioning Remains Entrenched Despite 5% Bond YieldsJune 13, 2026 7:00 AM
IH Market News

BofA’s Hartnett Warns Bullish Positioning Remains Entrenched Despite 5% Bond YieldsJune 13, 2026 7:00 AM
IH Market News

There's a lot of uncertainty around how this negotiations process with the First Nations even works. Unless you're in the mine start-up business, it's a long, sorted process between the potential miner, government agencies, and the Natives. These community votes may be in most part "window dressing"

Doc, the issue is not whether the SAP included bias checks. Of course it did. The issue is whether those checks were sufficient to prove the external control population was comparable enough to support treatment effect.

Bias checks can reduce concern, but they do not create randomizat

Yes. Quite entertaining.
https://www.linkedin.com/feed/update/urn:li:activity:7470142453950447616/

Yes, yes ...we all know what the bid and ask are.
You’re explaining mechanics like that’s the issue here, when the real problem is you’re trying to apply big-float logic to a 9.7M float. That’s why your whole “we need volume every day” argument falls apart.

You keep talking lik

Umm, they say Quantum was 20 years away. It's here today. Fusion is coming, and both (Fusion/Nuclear) will co-exist! 

Congrats SteveSchiets! And to Nsom as well. And thanks again to Sskillz1 for running these contests.

I recognize your name from another board . Let’s hope this ceo is far more competent and trustworthy, this moa while different tries to accomplish the same sort of endgame, a neuron closer to homeostasis .

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelomaJune 13, 2026 6:33 AM
PR Newswire (US)